D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., Maki, R. G. (October 2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol, 23 (28). pp. 7135-42. ISSN 0732-183X (Print)0732-183X (Linking)
Abstract
PURPOSE: To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS). PATIENTS AND METHODS: Patients may have had up to one nonanthracycline line of therapy. Seventeen patients with metastatic STS were treated with doxorubicin at 75 mg/m2 intravenous (IV) push followed by bevacizumab 15 mg/kg IV every 3 weeks. Dexrazoxane was started for total doxorubicin dose exceeding 300 mg/m2. RESULTS: A total of 85 cycles of doxorubicin/bevacizumab were administered, median four cycles (range, one to 11), with three patients receiving one to four cycles of bevacizumab maintenance after reaching 600 mg/m2 doxorubicin. All 17 patients were assessable for response. Two partial responses (12%, 95% CI = 1% to 36%) were observed, lasting seven and 12 cycles of therapy. Eleven patients (65%) had stable disease for four cycles or more. Six patients developed cardiac toxicity grade 2 or greater, with four patients grade 2 (cumulative doxorubicin 75, 150, 300, 300 mg/m2, respectively), one grade 3 (total doxorubicin 591 mg/m2), and one grade 4 (total doxorubicin 420 mg/m2). One patient with extensive lung disease died of recurrent bilateral pneumothoraces, possibly treatment-related. CONCLUSION: The 12% response rate for these patients was no greater than that observed for single-agent doxorubicin. However, the 65% of patients with stable disease lasting four cycles or longer suggests further study is warranted in STSs. The observed cardiac toxicity, despite close monitoring and standard use of dexrazoxane, obliges a change in the dose and/or schedule in future studies of this combination.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Aged Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Bevacizumab Doxorubicin/administration & dosage Female Humans Infusions, Intravenous Injections, Intravenous Male Middle Aged Neoplasm Metastasis Sarcoma/*drug therapy/*pathology Treatment Outcome |
| Subjects: | diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > metastasis diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | 1 October 2005 |
| Date Deposited: | 26 Oct 2016 20:20 |
| Last Modified: | 26 Oct 2016 20:20 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33657 |
Actions (login required)
 |
Administrator's edit/view item |